Dermorphin vs Pinealon
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
DermorphinCognitive EnhancementAnti-Aging & Longevity
Pinealon- Summary
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
- Half-Life
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
- Admin Route
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- SubQ, Oral, Intranasal
- Research
- —
- —
- Typical Dose
- Not established for human use; research doses vary widely
- 5–10 mg (oral) or 50–100 mcg (SC)
- Frequency
- Not established
- Once daily for 10 days
- Key Benefits
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Neuroprotection against oxidative stress and hypoxia
- Promotes neuronal regeneration and repair
- Improves memory and cognitive function
- Enhances sleep quality via melatonin regulation
- Anti-aging effects on brain cells
- May slow cognitive decline in neurodegeneration
- Improves cerebrovascular circulation
- Reduces neuroinflammation
- Side Effects
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Excellent safety profile in clinical use
- Rare: mild drowsiness
- Transient mild headache at initiation
- Injection site reaction (SC)
- Stacks With
- —
- —